Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
308.44
+15.03 (5.12%)
Dec 20, 2024, 4:00 PM EST - Market closed
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 376 employees as of December 31, 2023. The number of employees increased by 284 or 308.70% compared to the previous year.
Employees
376
Change (1Y)
284
Growth (1Y)
308.70%
Revenue / Employee
$204,290
Profits / Employee
-$1,379,441
Market Cap
6.73B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 376 | 284 | 308.70% |
Dec 31, 2022 | 92 | 21 | 29.58% |
Dec 31, 2021 | 71 | 29 | 69.05% |
Dec 31, 2020 | 42 | 13 | 44.83% |
Dec 31, 2019 | 29 | 12 | 70.59% |
Dec 31, 2018 | 17 | 9 | 112.50% |
Dec 31, 2017 | 8 | 0 | - |
Dec 31, 2016 | 8 | -2 | -20.00% |
Dec 31, 2015 | 10 | -100 | -90.91% |
Dec 31, 2014 | 110 | -24 | -17.91% |
Dec 31, 2013 | 134 | 10 | 8.06% |
Dec 31, 2012 | 124 | 2 | 1.64% |
Dec 31, 2011 | 122 | 10 | 8.93% |
Dec 31, 2010 | 112 | -15 | -11.81% |
Dec 31, 2009 | 127 | -2 | -1.55% |
Dec 31, 2008 | 129 | -46 | -26.29% |
Dec 31, 2007 | 175 | 29 | 19.86% |
Dec 31, 2006 | 146 | 28 | 23.73% |
Jan 12, 2005 | 118 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Grifols | 23,737 |
Chemed | 15,087 |
Bausch + Lomb | 13,300 |
Jazz Pharmaceuticals | 2,800 |
Legend Biotech | 1,826 |
Waystar Holding | 1,400 |
Glaukos | 907 |
MDGL News
- 26 days ago - Top 3 Health Care Stocks That May Dip This Month - Benzinga
- 6 weeks ago - Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
- 7 weeks ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® - GlobeNewsWire
- 7 weeks ago - Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings - Seeking Alpha
- 2 months ago - Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings - Seeking Alpha
- 2 months ago - Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis - GlobeNewsWire